These findings underscore the tissue-specific dynamics of the FGF system under metabolic stress, identifying FGF1 as a promising therapeutic target for addressing obesity- and aging-related metabolic dysfunction. This evidence concerns the gene FGF1 and obesity due to melanocortin 4 receptor deficiency.